Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CELC Stock Forecast 2026-2027
$87.43
Current Price
$4.26B
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CELC Price Targets
+100.2%
To High Target of $175.00
+88.7%
To Median Target of $165.00
+65.8%
To Low Target of $145.00
CELC Price Momentum
-4.4%
1 Week Change
-33.3%
1 Month Change
+577.2%
1 Year Change
-12.3%
Year-to-Date Change
-42.1%
From 52W High of $151.02
+675.4%
From 52W Low of $11.28
📊 TOP ANALYST CALLS
Did CELC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Celcuity is one of their latest high-conviction picks.
Latest CELC Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CELC has a bullish consensus with a median price target of $165.00 (ranging from $145.00 to $175.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $87.43, the median forecast implies a 88.7% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 65.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CELC Analyst Ratings
12
Buy
0
Hold
0
Sell
CELC Price Target Range
Low
$145.00
Average
$165.00
High
$175.00
Current: $87.43
Latest CELC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CELC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $171.00 |
| Jun 3, 2026 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $166.00 |
| Jun 3, 2026 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $145.00 |
| May 18, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 15, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 15, 2026 | Needham | Buy | Reiterates | $N/A | |
| May 4, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| May 4, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| May 4, 2026 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| May 4, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 27, 2026 | Citizens | Market Outperform | Initiates | $N/A | |
| Mar 26, 2026 | Stifel | Buy | Maintains | $N/A | |
| Mar 26, 2026 | Needham | Buy | Reiterates | $N/A | |
| Mar 17, 2026 | Needham | Buy | Reiterates | $N/A | |
| Mar 10, 2026 | Needham | Buy | Maintains | $N/A | |
| Dec 12, 2025 | Wells Fargo | Overweight | Initiates | $N/A | |
| Dec 2, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Nov 18, 2025 | Wolfe Research | Outperform | Initiates | $N/A | |
| Nov 17, 2025 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Nov 13, 2025 | Craig-Hallum | Buy | Maintains | $N/A |
Celcuity Inc. (CELC) Competitors
The following stocks are similar to Celcuity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Celcuity Inc. (CELC) Financial Data
Celcuity Inc. has a market capitalization of $4.26B with a P/E ratio of -23.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -275.2%.
Valuation Metrics
Market Cap
$4.26B
Enterprise Value
$4.24B
P/E Ratio
-23.1x
PEG Ratio
-1.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.1%
Current Ratio
12.3x
Debt/Equity
604.3x
ROE
-275.2%
ROA
-37.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Celcuity Inc. (CELC) Business Model
About Celcuity Inc.
What They Do
Develops targeted therapies for solid tumors.
Business Model
Celcuity Inc. operates as a clinical-stage biotechnology company that focuses on creating therapies targeting the PI3K/AKT/mTOR signaling pathway responsible for cancer cell proliferation. The company generates revenue through the development and commercialization of its lead product, gedatolisib, and the CELsignia companion diagnostic platform, which identifies patients suitable for specific cancer treatments.
Additional Information
The company is based in Minneapolis, Minnesota, and concentrates its research efforts primarily on breast and prostate cancers while exploring other tumor types. Celcuity’s innovative approach aims to enhance precision oncology by improving the detection and treatment of cellular abnormalities in cancer care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
155
CEO
Mr. Brian F. Sullivan
Country
United States
IPO Year
2017
Website
www.celcuity.comCelcuity Inc. (CELC) Latest News & Analysis
Latest News
Quick Summary
Celcuity shares fell 25% following a disappointing trial for its breast cancer treatment, which extended patient survival but did not meet previous trial results.
Why It Matters
Celcuity's 25% drop signals investor concern over the efficacy of its breast cancer treatment, potentially impacting future funding and market confidence in the company.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Celcuity's three-drug regimen has been reported to double survival likelihood for breast cancer patients, according to a recent announcement from the company.
Why It Matters
Celcuity's breakthrough in breast cancer treatment may boost its stock value, attract investment, and impact market perceptions of the biotech sector.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Celcuity Inc. (Nasdaq: CELC) will hold a conference call on June 2, 2026, to discuss results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 clinical trial.
Why It Matters
Celcuity's upcoming conference call on Phase 3 trial results could significantly impact stock performance, influencing investor sentiment and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Celcuity Inc. (NASDAQ:CELC) announced efficacy and safety results from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial on Tuesday.
Why It Matters
Celcuity's Phase 3 trial findings could impact its stock price and investor sentiment, indicating potential for drug approval and future revenue growth in targeted therapies.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
Celcuity Inc. (CELC) reported on the VIKTORIA-1 trial results, focusing on the efficacy of Gedatolisib for treating PIK3CA mutant advanced breast cancer.
Why It Matters
Celcuity's trial results for Gedatolisib in treating advanced breast cancer may indicate future revenue potential, impacting stock performance and investment decisions in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Celcuity Inc. announced positive efficacy and safety results from the Phase 3 VIKTORIA-1 trial of gedatolisib for PIK3CA mutant breast cancer, marking a first comparison of PAM inhibitors.
Why It Matters
The announcement of positive trial results for gedatolisib could boost Celcuity's stock, signaling potential revenue growth from a new treatment for breast cancer.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CELC Stock
What is Celcuity Inc.'s (CELC) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Celcuity Inc. (CELC) has a median price target of $165.00. The highest price target is $175.00 and the lowest is $145.00.
Is CELC stock a good investment in 2026?
According to current analyst ratings, CELC has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $87.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CELC stock?
Wall Street analysts predict CELC stock could reach $165.00 in the next 12 months. This represents a 88.7% increase from the current price of $87.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Celcuity Inc.'s business model?
Celcuity Inc. operates as a clinical-stage biotechnology company that focuses on creating therapies targeting the PI3K/AKT/mTOR signaling pathway responsible for cancer cell proliferation. The company generates revenue through the development and commercialization of its lead product, gedatolisib, and the CELsignia companion diagnostic platform, which identifies patients suitable for specific cancer treatments.
What is the highest forecasted price for CELC Celcuity Inc.?
The highest price target for CELC is $175.00 from at , which represents a 100.2% increase from the current price of $87.43.
What is the lowest forecasted price for CELC Celcuity Inc.?
The lowest price target for CELC is $145.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 65.8% increase from the current price of $87.43.
What is the overall CELC consensus from analysts for Celcuity Inc.?
The overall analyst consensus for CELC is bullish. Out of 5 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $165.00.
How accurate are CELC stock price projections?
Stock price projections, including those for Celcuity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 2:25 AM UTC